Qingqing Pan1,2, Xinxin Cao3, Yaping Luo4,5, Jian Li3, Jun Feng3, Fang Li1,2. 1. Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Wangfujing, Dongcheng District, 100730, Beijing, People's Republic of China. 2. Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Wangfujing, Dongcheng District, 100730, Beijing, People's Republic of China. 3. Department of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Wangfujing, Dongcheng District, 100730, Beijing, People's Republic of China. 4. Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Wangfujing, Dongcheng District, 100730, Beijing, People's Republic of China. luoyaping@live.com. 5. Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Wangfujing, Dongcheng District, 100730, Beijing, People's Republic of China. luoyaping@live.com.
Abstract
PURPOSE: 18F-FDG PET/CT has some limitations in the evaluation of multiple myeloma (MM). Since chemokine receptor-4 is overexpressed in MM, we perform a prospective cohort study to compare the performance of 68Ga-Pentixafor and 18F-FDG PET/CT in newly diagnosed MM. METHODS: Thirty patients with newly diagnosed MM were recruited. All patients underwent 68Ga-Pentixafor and18F-FDG PET/CT within 1 week after enrollment. A positive PET/CT was defined as the presence of focal PET-positive lesions in bone marrow or diffuse bone marrow patterns (uptake > liver). Bone marrow uptake values in 68Ga-Pentixafor and18F-FDG PET/CT (total bone marrow glycolysis [TBmGFDG], total bone marrow uptake with 68Ga-Pentixafor [TBmUCXCR4], total bone marrow volume [TBmV], SUVmean, and SUVmax) were obtained by drawing total bone marrow volume of interest on PET/CT. The positive rates of the PET/CT scans were statistically compared, and the correlation between quantitative bone marrow uptake values and clinical characteristics, laboratory findings, and staging was analyzed. RESULTS: 68Ga-Pentixafor PET/CT had a higher positive rate than 18F-FDG PET/CT in recruited patients (93.3 vs. 53.3%, p = 0.0005). In quantitative analysis, bone marrow uptake values in 68Ga-Pentixafor (TBmUCXCR4, SUVmax, and SUVmean) were positively correlated with end organ damage, staging, and laboratory biomarkers related to tumor burden including serum β2-microglobulin, serum free light chain, and 24-h urine light chain (p < 0.05). In 18F-FDG PET/CT, only the SUVmean of total bone marrow was positively correlated with serum free light chain and 24-h urine light chain (p < 0.05). CONCLUSIONS: 68Ga-Pentixafor PET/CT is promising in assessment of newly diagnosed MM. TRIAL REGISTRATION NUMBER: NCT03436342.
PURPOSE: 18F-FDG PET/CT has some limitations in the evaluation of multiple myeloma (MM). Since chemokine receptor-4 is overexpressed in MM, we perform a prospective cohort study to compare the performance of 68Ga-Pentixafor and 18F-FDG PET/CT in newly diagnosed MM. METHODS: Thirty patients with newly diagnosed MM were recruited. All patients underwent 68Ga-Pentixafor and18F-FDG PET/CT within 1 week after enrollment. A positive PET/CT was defined as the presence of focal PET-positive lesions in bone marrow or diffuse bone marrow patterns (uptake > liver). Bone marrow uptake values in 68Ga-Pentixafor and18F-FDG PET/CT (total bone marrow glycolysis [TBmGFDG], total bone marrow uptake with 68Ga-Pentixafor [TBmUCXCR4], total bone marrow volume [TBmV], SUVmean, and SUVmax) were obtained by drawing total bone marrow volume of interest on PET/CT. The positive rates of the PET/CT scans were statistically compared, and the correlation between quantitative bone marrow uptake values and clinical characteristics, laboratory findings, and staging was analyzed. RESULTS: 68Ga-Pentixafor PET/CT had a higher positive rate than 18F-FDG PET/CT in recruited patients (93.3 vs. 53.3%, p = 0.0005). In quantitative analysis, bone marrow uptake values in 68Ga-Pentixafor (TBmUCXCR4, SUVmax, and SUVmean) were positively correlated with end organ damage, staging, and laboratory biomarkers related to tumor burden including serum β2-microglobulin, serum free light chain, and 24-h urine light chain (p < 0.05). In 18F-FDG PET/CT, only the SUVmean of total bone marrow was positively correlated with serum free light chain and 24-h urine light chain (p < 0.05). CONCLUSIONS: 68Ga-Pentixafor PET/CT is promising in assessment of newly diagnosed MM. TRIAL REGISTRATION NUMBER: NCT03436342.
Authors: Yazan Alsayed; Hai Ngo; Judith Runnels; Xavier Leleu; Ujjal K Singha; Costas M Pitsillides; Joel A Spencer; Teresa Kimlinger; Joanna M Ghobrial; Xiaoying Jia; Ganwei Lu; Michael Timm; Ashok Kumar; Daniel Côté; Israel Veilleux; Karen E Hedin; G David Roodman; Thomas E Witzig; Andrew L Kung; Teru Hideshima; Kenneth C Anderson; Charles P Lin; Irene M Ghobrial Journal: Blood Date: 2007-04-01 Impact factor: 22.113
Authors: Thorsten Derlin; Faikah Gueler; Jan Hinrich Bräsen; Jessica Schmitz; Dagmar Hartung; Thomas R Herrmann; Tobias L Ross; Frank Wacker; Hans-Jürgen Wester; Marcus Hiss; Hermann Haller; Frank M Bengel; Katja Hueper Journal: J Nucl Med Date: 2017-04-27 Impact factor: 10.057
Authors: Constantin Lapa; Katharina Lückerath; Stefan Kircher; Heribert Hänscheid; Götz U Grigoleit; Andreas Rosenwald; Antje Stolzenburg; Saskia Kropf; Hermann Einsele; Hans-Jürgen Wester; Andreas K Buck; Klaus M Kortüm; Andreas Schirbel Journal: Br J Haematol Date: 2018-01-24 Impact factor: 6.998
Authors: Michele Cavo; Evangelos Terpos; Cristina Nanni; Philippe Moreau; Suzanne Lentzsch; Sonja Zweegman; Jens Hillengass; Monika Engelhardt; Saad Z Usmani; David H Vesole; Jesus San-Miguel; Shaji K Kumar; Paul G Richardson; Joseph R Mikhael; Fernando Leal da Costa; Meletios-Athanassios Dimopoulos; Chiara Zingaretti; Niels Abildgaard; Hartmut Goldschmidt; Robert Z Orlowski; Wee Joo Chng; Hermann Einsele; Sagar Lonial; Bart Barlogie; Kenneth C Anderson; S Vincent Rajkumar; Brian G M Durie; Elena Zamagni Journal: Lancet Oncol Date: 2017-04 Impact factor: 41.316
Authors: Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin Journal: J Clin Oncol Date: 2005-04-04 Impact factor: 44.544
Authors: Kathrin Philipp-Abbrederis; Ken Herrmann; Stefan Knop; Margret Schottelius; Matthias Eiber; Katharina Lückerath; Elke Pietschmann; Stefan Habringer; Carlos Gerngroß; Katharina Franke; Martina Rudelius; Andreas Schirbel; Constantin Lapa; Kristina Schwamborn; Sabine Steidle; Elena Hartmann; Andreas Rosenwald; Saskia Kropf; Ambros J Beer; Christian Peschel; Hermann Einsele; Andreas K Buck; Markus Schwaiger; Katharina Götze; Hans-Jürgen Wester; Ulrich Keller Journal: EMBO Mol Med Date: 2015-04 Impact factor: 12.137
Authors: Hans Jürgen Wester; Ulrich Keller; Margret Schottelius; Ambros Beer; Kathrin Philipp-Abbrederis; Frauke Hoffmann; Jakub Šimeček; Carlos Gerngross; Michael Lassmann; Ken Herrmann; Natalia Pellegata; Martina Rudelius; Horst Kessler; Markus Schwaiger Journal: Theranostics Date: 2015-03-01 Impact factor: 11.556
Authors: Constantin Lapa; Ken Herrmann; Andreas Schirbel; Heribert Hänscheid; Katharina Lückerath; Margret Schottelius; Malte Kircher; Rudolf A Werner; Martin Schreder; Samuel Samnick; Saskia Kropf; Stefan Knop; Andreas K Buck; Hermann Einsele; Hans-Juergen Wester; K Martin Kortüm Journal: Theranostics Date: 2017-04-08 Impact factor: 11.556
Authors: Marius E Mayerhoefer; Markus Raderer; Wolfgang Lamm; Verena Pichler; Sarah Pfaff; Michael Weber; Barbara Kiesewetter; Markus Hacker; Lukas Kazianka; Philipp B Staber; Hans-Juergen Wester; Johannes Rohrbeck; Ingrid Simonitsch-Klupp; Alexander Haug Journal: Theranostics Date: 2021-01-01 Impact factor: 11.556
Authors: Marius E Mayerhoefer; Markus Raderer; Wolfgang Lamm; Michael Weber; Barbara Kiesewetter; Johannes Rohrbeck; Ingrid Simonitsch-Klupp; Marcus Hacker; Asha Leisser; Lukas Nics; Stefan Schmitl; Hans-Juergen Wester; Alexander Haug Journal: Blood Date: 2022-01-13 Impact factor: 22.113